Patent application number | Description | Published |
20100243758 | LIQUID STORAGE CONTAINER FOR A PAINTING DEVICE - A liquid storage container for a painting device includes a container for storing paint. The container is connected with a lid by screw fastening. The top of the lid has a connecting part with a hole. A flow guide element extends from below the hole. The glow guide element has a channel in fluid communications with the hole. The other end of the channel has a first glow guide in fluid communication with the inside of the container. A steel ball is disposed in the upper portion of the channel with one side urging against the surrounding of the hole. The other side of the steel ball is urged by a spring. The other end of the spring urges against the bottom of the channel. | 09-30-2010 |
20100252143 | FILLING STRUCTURE OF A PAINTING DEVICE - A filling structure of a painting device includes a combining base and an urging element. The top surface of the combining base has a combining tank, the bottom of which is formed with a through hole for the disposition of an urging element. The bottom of the combining base has a combining part for connecting to a painting device. The urging element has a guiding channel inside. One end of the guiding channel is inside the combining tank, and the other end is inside the painting device. | 10-07-2010 |
20120056015 | SPRAYER WITH AN IMPROVED SPRAYING STRUCTURE - A sprayer with an improved spraying structure comprises a body, a nozzle, a knob, and a nozzle sleeve. The body has a passage and a valve. At the end of the passage is an air outlet. A mounting part with an insertion hole is provided around the body. The assembly of the nozzle, the knob, and the nozzle sleeve is inserted in the mounting part. The paint bottle with paint is connected to the knob. | 03-08-2012 |
Patent application number | Description | Published |
20090047688 | REAGENTS, KITS AND METHODS FOR DETECTING BIOLOGICAL MOLECULES BY ENERGY TRANSFER FROM AN ACTIVATED CHEMILUMINESCENT SUBSTRATE TO AN ENERGY ACCEPTOR DYE - Reagents, kits and methods for detecting biological molecules by energy transfer from an activated chemiluminescent substrate to an energy acceptor dye such as a J-aggregated dye are described. | 02-19-2009 |
20110003277 | Dioxetane-Nanoparticle Assemblies For Energy Transfer Detection Systems, Methods Of Making The Assemblies, And Methods Of Using The Assemblies in Bioassays - Assemblies comprising nanoparticles and chemiluminescent substrates such as dioxetanes are provided. The assemblies can be used in assays to detect the presence and/or amount of a single analyte or multiple analytes in a sample. Methods of making the assemblies are also described. | 01-06-2011 |
20120100566 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES - Chemiluminescent compositions, methods, assays and kits for oxidative enzymes are described. Further disclosed are dioxetane compounds of the form: 0-0 ΛR R R T (i) where R can independently be any branched alkyl or cycloalkyl group which provides stabilization for the dioxetane or where both R groups together form a cycloalkyl or polycycloalkyl moiety spiro bound to the dioxetane ring, wherein each R group or the spiro bound moiety can be unsubstituted or substituted with one or more electron-withdrawing groups or electron donating groups, or groups providing preferential oxidative isozyme substrate recognition, and wherein Ri is an aryl group, or an alkyl group of 1-20 carbon atoms, which can be optionally substituted with 1 or more halogen atoms, and wherein T is an aryl or heteroaryl ring capable of emitting light upon enzyme activated decomposition of the dioxetane I. Kits, methods and assays are also disclosed that comprise the dioxetane compounds. | 04-26-2012 |
Patent application number | Description | Published |
20120028827 | METHOD FOR DETERMINING A RISK, FOR A SUBJECT, OF SUFFERING FROM ATOPIC DERMATITIS OR SEVERITY OF ATOPIC DERMATITIS FOR A SUBJECT SUFFERING FROM ATOPIC DERMATITIS AND METHOD FOR USING A SINGLE-NUCLEOTIDE POLYMORPHISM RS12313273 AS A BIOMARKER FOR DETERMINING THE DEVELOPMENT OR SEVERITY OF ATOPIC DERMATITIS - The invention provides a method for determining a risk, for a subject, of suffering from atopic dermatitis, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining the risk, for the subject, of suffering from atopic dermatitis, wherein the presence of a C allele or genotype CC of the single-nucleotide polymorphism rs12313273 (C/T) indicates that the subject is at increased risk for suffering from atopic dermatitis. | 02-02-2012 |
20120252867 | METHOD OF THERAPY AND DIAGNOSIS OF ATHEROSCLEROSIS - There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis. | 10-04-2012 |
20130040996 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF - Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL). | 02-14-2013 |
20140194474 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF - Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL). | 07-10-2014 |
Patent application number | Description | Published |
20100015645 | IL-8 AS BIOMARKER FOR THE DETECTION OF UROLITHIASIS - Disclosed herein is a method for the detection or preliminary screening of urolithiasis, comprising: detecting the IL-8 level and the creatinine level in a urine sample taken from a human subject suspected to have urolithiasis; obtaining a creatinine-normalized IL-8 level in the urine sample by normalizing the detected IL-8 level to the detected creatinine level; and comparing the creatinine-normalized IL-8 level in the urine sample with a predetermined standard; wherein an elevation of the creatinine-normalized IL-8 level in the urine sample as compared to the predetermined standard is indicative of urolithiasis. | 01-21-2010 |
20100021889 | USING GENETIC POLYMORPHISMS OF THE BICD1 GENE AS A METHOD FOR DIAGNOSING AND TREATING MYOPIA - Using the BICD | 01-28-2010 |
20110129838 | USING GENETIC POLYMORPHISMS OF THE BICD1 GENE AS A METHOD FOR DETERMINING A RISK OF DEVELOPING MYOPIA - A method and kit for determining an increased risk of developing myopia in a subject is provided by detecting an SNP in the BICD1 gene. The SNP is selected from a group consisting of rs10844126 (A/C), rs1151029 (A/T), rs2650122 (C/T), rs10771923 (A/G), rs1151009 (T/C), rs2125173 (A/G) and rs161959 (C/G). When the presence of the risk allele associated with myopia is detected at the SNP, the subject is determined in an increased risk of developing myopia. | 06-02-2011 |
20110142913 | COMPOSITION AND METHOD FOR TREATING ATHEROSCLEROSIS, METHOD FOR DETERMINING IF A SUBJECT HAS ATHEROSCLEROSIS AND METHOD OF SCREENING AN ANTI-ATHEROSCLEROTIC DRUG - The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis. | 06-16-2011 |
20120329853 | MICRORNA-BASED METHOD FOR ANTI-COLORECTAL CANCER EFFECTS AND PROGNOSIS OF COLORECTAL CANCER - The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer. | 12-27-2012 |
20130137597 | Microrna-based method for anti-colorectal cancer effects and prognosis of colorectal cancer - The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer. | 05-30-2013 |
Patent application number | Description | Published |
20120100539 | METHOD FOR DETERMINING RISK FOR KIDNEY STONES DEVELOPING OR RECURRING AND METHOD FOR USING SINGLE-NUCLEOTIDE POLYMORPHISM RS12313273 AS BIOMARKER FOR DETERMINING DEVELOPMENT OR RECURRENCE OF KIDNEY STONE - The invention provides a method for determining a risk for kidney stones to develop in a subject, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining a risk for kidney stones to develop in the subject, wherein if the presence of a C allele of the single-nucleotide polymorphism rs12313273 (C/T) is detected, it indicates that the subject has an increased risk for kidney stones to develop. | 04-26-2012 |
20120196293 | METHOD AND KIT FOR IN VITRO DIAGNOSIS OF ATHEROSCLEROSIS - A method for in vitro diagnosis of atherosclerosis, comprising: (a) obtaining a sample from a subject; (b) determining expression levels of one or more microRNAs (miRNAs) as atherosclerotic biomarkers and an internal control RNA; (c) computing the relative expression levels of the one or more miRNAs as atherosclerotic biomarkers; (d) computing a prediction model with one or more variables, wherein the variable includes one or more relative expression levels of the one or more miRNAs as atherosclerotic biomarkers and one or more risk factors of atherosclerosis; and (e) computing a prediction probability by the prediction model, wherein the subject is diagnosed with atherosclerosis if the probability is more than 0.5 is presented. A kit for in vitro diagnosis of atherosclerosis or prognosis of atherosclerosis-inducing diseases is also presented. | 08-02-2012 |
20120245108 | METHOD OF MODULATING COMPLEMENT FACTOR B (CFB) EXPRESSION IN CELLS - The present invention relates to a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells. This method can be applied in treating or prophylaxis of the disease, disorder or medical condition associated to complement factor B (CFB) expression. | 09-27-2012 |
20130089601 | METHOD FOR TREATING ATHEROSCLEROSIS - The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector. | 04-11-2013 |